BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)
| 7.07 Delayed Data As of Sep 29 |  -0.17 / -2.35%Today’s Change | 6.62 Today|||52-Week Range 14.50 | -38.41% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.3B |
Company Description
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.
Contact Information
BioCryst Pharmaceuticals, Inc. 4505 Emperor Boulevard Durham North Carolina 27703-8457 |
Employees
Shareholders
| Other institutional | 57.99% |
| Mutual fund holders | 34.56% |
| Individual stakeholders | 12.60% |
Top Executives
| Jon P. Stonehouse | President, Chief Executive Officer & Director |
| Michael L. Jones | Executive Director-Finance |
| Anthony Doyle | Chief Financial & Accounting Officer |
| Helen M. Thackray | Chief Research & Development Officer |
| Ryan Arnold | Chief Medical Officer |
